Exchange: NASDAQ·Updated 05:04 PM EDT

HRMY News

News
all
press releases
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
Zacks
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.
Zacks
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.
Zacks
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.
Zacks
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
Zacks
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Zacks
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.
Zacks
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Zacks

Advertisement|Remove ads.